What is Oxular?
Oxular is a development-stage company dedicated to transforming treatments for retinal diseases through advanced therapeutic approaches. The company leverages proprietary drug formulation and ocular administration technology to create novel solutions for conditions affecting the retina. Its focus on unmet needs within ophthalmology positions it as a key player in the specialized field of retinal therapeutics. The recent major strategic investment suggests a transition towards scaling its development and potentially commercialization efforts.
How much funding has Oxular raised?
Oxular has raised a total of $37M across 1 funding round:
Other Financing Round
$37M
Other Financing Round (2021): $37M with participation from NeoMed Management, Forbion, V-Bio Ventures, and The IP Group
Key Investors in Oxular
NeoMed Management
NeoMed Management is an international venture capital firm exclusively focused on the healthcare industry, investing in emerging companies with outstanding growth prospects in pharmaceuticals, medical devices, and diagnostics.
Forbion
Forbion is a prominent European venture capital firm specializing in life sciences, with a focus on developing and investing in companies with innovative therapeutic solutions.
V-Bio Ventures
V-Bio Ventures is a life science venture capital fund that invests in early- to mid-stage companies with high growth potential, particularly in therapeutics, leveraging its network to transform scientific innovations into impactful products.
What's next for Oxular?
With the recent influx of major strategic investment, Oxular is poised to accelerate its development pipeline and further refine its ocular administration technology. The enterprise-level backing indicates a strong foundation for growth, likely enabling the company to advance its therapeutic candidates through critical clinical stages. Future strategic partnerships or further financing rounds may be anticipated as Oxular aims to bring its innovative retinal treatments to market, addressing significant unmet needs in the ophthalmology sector.
See full Oxular company page
